Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Apolipoprotein M in patients with chronic kidney disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of simvastatin and ezetimibe on suPAR levels and outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exercise-Based Rehabilitation for Heart Failure: Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND AND AIMS: Raised levels of serum endostatin, a biologically active fragment of collagen XVIII, have been observed in patients with ischemic heart disease but association with incident cardiovascular events in patients with stable coronary heart disease is uncertain.

METHODS: The CLARICOR-trial is a randomized, placebo-controlled trial of stable coronary heart disease patients evaluating 14-day treatment with clarithromycin. The primary outcome was a composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease or all-cause mortality. In the present sub-study using 10-year follow-up data, we investigated associations between serum endostatin at entry (randomization) and the composite outcome and its components during follow-up. The placebo group was used as discovery sample (1204 events, n = 1998) and the clarithromycin-treated group as replication sample (1220 events, n = 1979).

RESULTS: In Cox regression models adjusting for cardiovascular risk factors, glomerular filtration rate, and current pharmacological treatment, higher serum endostatin was associated with an increased risk of the composite outcome in the discovery sample (hazard ratio per standard deviation increase 1.11, 95% CI 1.03-1.19, p = 0.004), but slightly weaker and not statistically significant in the replication sample (hazard ratio 1.06, 95% CI 1.00-1.14, p = 0.06). In contrast, strong and consistent associations were found between endostatin and cardiovascular and all-cause mortality in all multivariable models and sub-samples. Addition of endostatin to a model with established cardiovascular risk factors provided no substantial improvement of risk prediction (<1%).

CONCLUSIONS: Raised levels of serum endostatin might be associated with cardiovascular events in patients with stable coronary heart disease. The clinical utility of endostatin measurements remains to be established.

OriginalsprogEngelsk
TidsskriftAtherosclerosis
Vol/bind284
Sider (fra-til)202-208
Antal sider7
ISSN0021-9150
DOI
StatusUdgivet - 2019

Bibliografisk note

Copyright © 2019 Elsevier B.V. All rights reserved.

ID: 56951566